Member Info for Krustysmegma

Please, please can we have no more conspiracy theories about something being hidden in the data that they're not telling us. It's clear now that there is at least one potential "partner" who wishes to see SDC-1801 taken down the P2 route with a longer study & larger cohort of patients, hence the need for additional clinical safety work. This, in my view, is excellent news and the best possible direction of travel. If it takes another 6 months, so be it. Hearing it from the horses mouth will surely now kill off any more ridiculous speculation.

Cjh, I've said it before & no doubt I'll have to say it again, if you've been here for 15 years you've had plenty of opportunities to top-slice and lock in profits.

Ted, I'm referring to the "Analysis of blood samples from trial participants who received SDC-1801 for 10 days in the MAD cohorts demonstrated clear, dose-responsive reductions in three biomarkers of JAK1 and/or TYK2 activity" and I did add (subject to trials in a cohort of psoriasis patients) so I think my comment was fair. Of course efficacy still has to be established, or we'd all be millionaires by now. Believe me, I share people's frustration at the slow/lack of reported progress here but I do feel at times this is overdone and plays into the hands of the doom & gloom brigade, hence trying to put a different interpretation on this morning's report.

In summary:

"The success of this trial highlights that high blood levels of our dual TYK2/JAK1 kinase inhibitor can be achieved without serious side effects. Moreover, based on the unblinded data now available, we are pleased to note that the frequency of adverse events (all mild or moderate) was similar in the active and placebo groups. No clinically significant effects on any component of blood, which have been affected by earlier generation JAK inhibitors, were observed. The observed favourable safety and pharmacokinetic profiles may give SDC-1801 significant advantage over competitors."

"Analysis of blood samples from trial participants who received SDC-1801 for 10 days in the MAD cohorts demonstrated clear, dose-responsive reductions in three biomarkers of JAK1 and/or TYK2 activity. This provides strong evidence that safe blood levels of SDC-1801 were able to significantly inhibit major inflammatory pathways."

"In addition, post the financial year end, we secured £3.4 million before expenses in funding through subscriptions, and received a A$1.9 million (c. £1 million) Australian tax credit ."

So our lead compound is safe, it appears to work (subject to trials in a cohort of psoriasis patients) and there are HNWI's, corporates and II's who want to invest. There must be junior pharma's up & down the land dreaming of having a year like this. If you can't see what's coming here you should probably call it a day. For those of us who can, strap in & prepare for the ride. It could be spectacular!!

Wonder if they'll look to buy us out?

I guess the average timescale includes the likes of AZ, GSK etc. for whom funding is not an issue. Once their development budgets have been agreed ($bns) they can plan and execute their pre-clinical and clinical programmes for the year ahead. Unlike SAR who have been constrained at all junctures by lack of resource and, as this last year has proved, lack of skills necessary to exploit what may have been available. So I'm not sure we can learn much from averages & comparisons.

Question is, how many more vessels can they dispose of whilst maintaining the dividend at the current level? Dividend cover is down to 1.1x (was almost 4x in the early TMIP days) and the look-through debt-to-gross assets has only marginally reduced from 35.4% to 35.1% despite the numerous disposals. What I liked was the purchase & subsequent sale and charter back JV of a 63K dwt Ultramax vessel for a decent profit. Hope they've got one or two more similar deals in the pipeline, that would help to move things along.

RIO tipped as "Large-Cap Value Play" in today's magazine:

"Based on consensus forecasts Rio is on a 2025 price to earnings ratio of 9.6 times and offers a dividend yield of 6.1%. Given the generous dividends, investors are being paid to wait for the shares to return to their long-term average rating of around 12 times earnings."

The.Italian, it's very positive:

"There are always extra risks to consider when investing in smaller companies operating with a single product, but we believe that for investors with the appetite and patience, an investment in Futura Medical could pay off handsomely."

bull****repeat, if you want intelligent commentary then post something credible. when was trp sp £16.50? when was the mcap c. £18bn as your ridiculous post claims? come on, you can do better than that surely??

Excellent update, things are beginning to look really good again here. Should be able to raise the dividend soon, and as the yield is already over 8% that should mean the SP can move towards £1.00 - £1.10 range.

comment. trp never has been, and never will be, worth £18bn so i suggest you throw your *** packet away & start again. i didn't bother reading the rest of your post.

Thanks for the full explanation colbalt, hopefully others will read and take note. Best wishes. K

Wow, this board can be a real pain at times but every now & again I'm reminded why I still come on here occasionally. Great advice RICH3R, glad things are now improving for you. Salford, lovely post & very poignant after all you've both been through. Desamax, hope all goes well for you and that you make a full recovery. Following discovery of my own enlarged prostate, I have a PSA test every 6 months and strongly advise men over 60 to engage with the process. Colbalt, you won't remember but I'll never forget the advice you gave me and will be forever grateful for it. I've sadly lost a close friend to sepsis following the exact procedure you warned me about (I had no idea so wasn't able to warn him), so thank you once again.

I had planned to buy more @ 25p as posted on here, but since the Board has now issued cheaper shares to HNWI's and others I've had to revise my thoughts. I've always managed to buy at lower prices than the HNWI's after waiting for the price to drop (I can't beat the 10p offer but we all had the same opportunity there) so 20p would suit my personal agenda. We all know this will fly sooner or later (or plunge, I know) and it's incredibly frustrating waiting for it to happen, but as I've said many, many times before, this isn't the kind of share where you buy once and wait. You have to keep chipping away, and that means (in my case) finding funds to invest whenever the price is low. In my personal view we won't see 20p but if we do, I'll be ready. GLA.

Agreed.

Hmm, CFO left suddenly on Friday with no explanation. She'd only been in post for 4 months. There may be a perfectly good explanation, but they're not giving it if there is. So, this is very much on negative watch for me for the time being and I won't be adding to my holding.

The big seller had been driving the price down so no point buying until they'd cleared. Once cleared, the SP should rise so good time to buy. That's the theory at least, or so I believe.

This would be a "bag" for me at just over 215, normally that would trigger me to sell half & run the other half effectively for free. However, I believe there is so much more to come here I'm actually inclined to double up & increase my average. One of my best investments so far.

Yes I keep reading about that ESSEXDOG, was it easy to set up? It's a variable rate presumably, so could reduce at a moment's notice? Very tempting with no platform fee though, I might have a look.